like all other appointments I only can see higher costs and higher cash burn. Cant follow for what all this appointments are for if we have not a single product not even a phase 3 trial as far as I know. Let apart not even a well known Private Equity company on board. We are down 90% btw. Market already priced in the value of all other appointments I guess. IMO and perception
Ann: Imugene Appoints Kim Drapkin as Non-Executive Director, page-80
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.8¢ |
Change
-0.002(4.00%) |
Mkt cap ! $356.9M | |||
| Open | High | Low | Value | Volume |
| 5.0¢ | 5.0¢ | 4.8¢ | $382.1K | 7.853M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 62 | 8072405 | 4.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.9¢ | 668099 | 5 |
View Market Depth
| Last trade - 16.10pm 03/10/2024 (20 minute delay) ? |
| IMU (ASX) Chart |